Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients

Abstract

The global pandemic caused by coronavirus disease 2019 (COVID-19) has caused more than 1 million deaths worldwide. Some vaccines in clinical trials have reached stage 3. In the meantime, the understanding of biological and pathophysiological mechanisms of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is still unclear, such as the role that angiotensin-II conversion enzyme (ACE-2) and dipeptidyl-peptidase 4 (DPP-IV) may play in patients with diabetes related to COVID-19. The individual with diabetes is a known COVID-19 risk patient. Probably, the pharmacological regulation of the angiotensin renin system and ACE-2 on the one hand, and of the incretin system and DPP-IV on the other hand, could represent a therapeutic route of fundamental importance to reduce the risk of SARS-CoV-2 infection or of severe complications caused by infection.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

John Hopkins University. Available from: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

World Health Organization (WHO). DRAFT landscape of COVID-19 candidate vaccines. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 doi: 10.1007/s00134-020-05991-x. [Epub ahead of print]. DOI: https://doi.org/10.1007/s00134-020-05991-x

Vitiello A, Ferrara F. Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: what do we know. Eur J Pharmacol 2020;883:173373. DOI: https://doi.org/10.1016/j.ejphar.2020.173373

Jian S, Yushun W, Chuming L. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 2020;117:11727-34. DOI: https://doi.org/10.1073/pnas.2003138117

Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 2020;9:601-4. DOI: https://doi.org/10.1080/22221751.2020.1739565

Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-72. DOI: https://doi.org/10.1007/s00125-005-1749-8

Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 2020;262:118510. DOI: https://doi.org/10.1016/j.lfs.2020.118510

Vitiello A, Ferrara F. Therapeutic strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci 2020;105579. DOI: https://doi.org/10.1016/j.ejps.2020.105579

Lambeir AM, Durinx C, Scharpe S, DeMeester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.

Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73. DOI: https://doi.org/10.1078/0171-9335-00302

Lambeir AM. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94. DOI: https://doi.org/10.1080/713609354

Kaufman MB. ACE inhibitor-related angioedema: are your patients at risk?. P T. ? 2013;38:170-2.

Published
2020-12-28
Info
Issue
Section
Brief Reports
Keywords:
Diabetes, COVID-19, SARS-CoV-2, angiotensin- II conversion enzyme, dipeptidyl-peptidase 4.
Statistics
  • Abstract views: 255

  • PDF: 140
  • HTML: 0
How to Cite
Ferrara, F., & Vitiello, A. (2020). Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients. Italian Journal of Medicine, 15(1). https://doi.org/10.4081/itjm.2020.1435